10,11-dihydroxy-N-allylnoraporphine, often abbreviated as **DHAN**, is a synthetic derivative of the alkaloid aporphine. It's important for research because of its potential therapeutic applications in treating neurological disorders.
Here's a breakdown of its importance:
**What it is:**
* **Aporphine derivative:** DHAN is structurally similar to naturally occurring aporphine alkaloids, which are found in various plants.
* **Synthetic:** DHAN is not found naturally and must be synthesized in a lab.
* **N-allyl group:** This structural modification differentiates DHAN from other aporphine derivatives.
**Why it's important for research:**
* **Neuroprotective effects:** Studies have shown that DHAN exhibits neuroprotective properties, potentially protecting neurons from damage caused by oxidative stress, inflammation, and other factors that contribute to neurodegenerative diseases.
* **Antioxidant activity:** DHAN possesses strong antioxidant activity, which may be beneficial in combating oxidative stress, a major contributing factor to aging and disease.
* **Possible therapeutic potential for neurological disorders:** Due to its neuroprotective and antioxidant properties, DHAN is being investigated as a potential treatment for various neurological conditions, including Alzheimer's disease, Parkinson's disease, and stroke.
* **Potential for drug development:** The research on DHAN could lead to the development of new and effective therapies for neurological disorders.
**Current research focus:**
* Understanding the exact mechanisms of DHAN's neuroprotective and antioxidant effects.
* Investigating its efficacy and safety in preclinical models of neurological disorders.
* Developing novel drug delivery systems for DHAN to enhance its bioavailability and therapeutic efficacy.
While research on DHAN is promising, it's still in its early stages. More research is needed to fully understand its potential and ensure its safety and efficacy in humans.
10,11-dihydroxy-N-allylnoraporphine: RN refers to (R)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 838674 |
CHEMBL ID | 318111 |
CHEBI ID | 92130 |
SCHEMBL ID | 12305058 |
MeSH ID | M0183890 |
Synonym |
---|
CHEMBL318111 , |
4h-dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-(2-propenyl)-, (r)- |
18426-17-0 |
10,11-dihydroxy-n-allylnoraporphine |
BRD-K07079548-001-01-9 |
(r)-6-allyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol |
BPBIO1_001351 |
BIOMOL-NT_000063 |
LOPAC0_000406 |
NCGC00162144-03 |
(r)6-allyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol |
6-allyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol; hydrobromide |
bdbm50007423 |
cid_11957524 |
CCG-204499 |
SCHEMBL12305058 |
CHEBI:92130 |
(8r)-7-prop-2-enyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-13,14-diol |
Q27163914 |
6-(prop-2-en-1-yl)-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol |
DTXSID90939810 |
SDCCGSBI-0050392.P002 |
(6ar)-6-prop-2-enyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol |
r(-)-n-allylnorapomorphine |
AKOS040757092 |
Class | Description |
---|---|
aporphine alkaloid | Any benzylisoquinoline alkaloid that has a structure based on 4H-dibenzo[de,g]quinoline or its 3-methyl derivative. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
dopamine D1 receptor | Homo sapiens (human) | Potency | 0.0517 | 0.0052 | 1.3022 | 8.1995 | AID624455 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 4.2743 | 0.1000 | 20.8793 | 79.4328 | AID488773; AID588453; AID588456 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 32.6294 | 0.0041 | 10.8903 | 31.5287 | AID493107 |
GLS protein | Homo sapiens (human) | Potency | 0.8913 | 0.3548 | 7.9355 | 39.8107 | AID624146 |
hypothetical protein, conserved | Trypanosoma brucei | Potency | 13.4591 | 0.2239 | 11.2451 | 35.4813 | AID624147 |
regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 33.5875 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
Parkin | Homo sapiens (human) | Potency | 32.6427 | 0.8199 | 14.8306 | 44.6684 | AID720573 |
arylsulfatase A | Homo sapiens (human) | Potency | 37.9330 | 1.0691 | 13.9551 | 37.9330 | AID720538 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 0.5323 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 58.4789 | 0.0165 | 25.3078 | 41.3999 | AID602332 |
NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 58.0479 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
D(1A) dopamine receptor | Homo sapiens (human) | Potency | 0.4661 | 0.0224 | 5.9449 | 22.3872 | AID488981; AID488982; AID488983 |
vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 10.0000 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 44.6684 | 0.0060 | 26.1688 | 89.1251 | AID488953 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 58.0479 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 16.7418 | 0.0037 | 8.6189 | 23.2809 | AID2667; AID2668 |
M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 23.7781 | 0.1778 | 24.7352 | 79.4328 | AID488949 |
histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
D(1A) dopamine receptor | Sus scrofa (pig) | Potency | 7.3621 | 0.0037 | 8.1081 | 23.2809 | AID2667 |
Ataxin-2 | Homo sapiens (human) | Potency | 35.4813 | 0.0119 | 12.2221 | 68.7989 | AID588378 |
2,3-bisphosphoglycerate-independent phosphoglycerate mutase | Leishmania major strain Friedlin | Potency | 37.9330 | 7.5686 | 15.2306 | 21.3313 | AID504548 |
ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 4.7755 | 0.0601 | 10.7453 | 37.9330 | AID485368 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
negative regulation of receptor internalization | Ataxin-2 | Homo sapiens (human) |
regulation of translation | Ataxin-2 | Homo sapiens (human) |
RNA metabolic process | Ataxin-2 | Homo sapiens (human) |
P-body assembly | Ataxin-2 | Homo sapiens (human) |
stress granule assembly | Ataxin-2 | Homo sapiens (human) |
RNA transport | Ataxin-2 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
RNA binding | Ataxin-2 | Homo sapiens (human) |
epidermal growth factor receptor binding | Ataxin-2 | Homo sapiens (human) |
protein binding | Ataxin-2 | Homo sapiens (human) |
mRNA binding | Ataxin-2 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
cytoplasm | Ataxin-2 | Homo sapiens (human) |
Golgi apparatus | Ataxin-2 | Homo sapiens (human) |
trans-Golgi network | Ataxin-2 | Homo sapiens (human) |
cytosol | Ataxin-2 | Homo sapiens (human) |
cytoplasmic stress granule | Ataxin-2 | Homo sapiens (human) |
membrane | Ataxin-2 | Homo sapiens (human) |
perinuclear region of cytoplasm | Ataxin-2 | Homo sapiens (human) |
ribonucleoprotein complex | Ataxin-2 | Homo sapiens (human) |
cytoplasmic stress granule | Ataxin-2 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504836 | Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation | 2002 | The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16 | Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588378 | qHTS for Inhibitors of ATXN expression: Validation | |||
AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347050 | Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1347045 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
AID588349 | qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay | |||
AID1347049 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
AID65276 | Compound was evaluated for its ability to inhibit Dopamine receptor D2 in rat striatum using [3H]spiperone | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1 | R and S enantiomers of 11-hydroxy- and 10,11-dihydroxy-N-allylnoraporphine: synthesis and affinity for dopamine receptors in rat brain tissue. |
AID63013 | Compound was evaluated for its ability to inhibit Striatal Dopamine receptor in rat brain through radioreceptor assay carried out with agonist ligand. | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1 | R and S enantiomers of 11-hydroxy- and 10,11-dihydroxy-N-allylnoraporphine: synthesis and affinity for dopamine receptors in rat brain tissue. |
AID61505 | Compound was evaluated for its ability to inhibit Dopamine receptor D1 in rat striatum using [3H]SCH-23390 | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1 | R and S enantiomers of 11-hydroxy- and 10,11-dihydroxy-N-allylnoraporphine: synthesis and affinity for dopamine receptors in rat brain tissue. |
AID226743 | Potency ratio calculated from the ratio of D2 to that of D1 receptors | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1 | R and S enantiomers of 11-hydroxy- and 10,11-dihydroxy-N-allylnoraporphine: synthesis and affinity for dopamine receptors in rat brain tissue. |
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (12.50) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 3 (37.50) | 24.3611 |
2020's | 3 (37.50) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.65) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |